Statements (74)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:academic_advisor |
engaged scientific advisors
|
| gptkbp:acquisition |
Medi Gene AG acquired by a consortium
|
| gptkbp:biologics |
developing biologics for cancer
|
| gptkbp:business_model |
focused on R& D
|
| gptkbp:ceo |
Helen Sabzevari
|
| gptkbp:clinical_trial |
ongoing
Phase 2 Phase 1/2 focused on innovative therapies results published in journals active enrollment in trials innovative clinical trial design multiple clinical trial phases positive clinical data reported positive clinical trial outcomes regular updates on trials results from clinical trials |
| gptkbp:collaboration |
academic institutions
|
| gptkbp:collaborations |
numerous research collaborations
various biotech companies with leading universities |
| gptkbp:collaborative_projects |
various collaborative projects
|
| gptkbp:financial_reports |
quarterly financial reports
|
| gptkbp:focus |
gptkb:immunotherapy
|
| gptkbp:founded |
gptkb:1997
|
| gptkbp:funding |
secured research funding
|
| gptkbp:has_advisory_board |
composed of industry experts
|
| gptkbp:head_of_state |
active business development efforts
|
| gptkbp:headquarters |
gptkb:Planegg,_Germany
|
| gptkbp:healthcare |
focus on therapeutic innovation
|
| https://www.w3.org/2000/01/rdf-schema#label |
Medigene AG
|
| gptkbp:initiatives |
various research initiatives
|
| gptkbp:instruction_set |
clinical pipeline
|
| gptkbp:invention |
multiple patents granted
|
| gptkbp:investment |
institutional investors
venture capital funding active investor relations program frequent investor updates regular investor presentations |
| gptkbp:investment_focus |
global market
|
| gptkbp:investment_strategy |
monitored by analysts
|
| gptkbp:leadership |
experienced management team
|
| gptkbp:location |
gptkb:Germany
|
| gptkbp:market_cap |
approximately €200 million
|
| gptkbp:marketing_strategy |
focused market strategy
|
| gptkbp:number_of_employees |
51-200
|
| gptkbp:partnership |
gptkb:Astellas_Pharma
established business partnerships |
| gptkbp:partnerships |
strategic partnerships
exploring partnership opportunities |
| gptkbp:product |
T-cell therapies
ongoing product development |
| gptkbp:publications |
numerous scientific publications
|
| gptkbp:regulatory_compliance |
FDA approval
submissions to regulatory authorities |
| gptkbp:research |
conducting scientific research
|
| gptkbp:research_areas |
gptkb:cancer_treatment
oncology cell-based therapies multiple therapeutic candidates in development dedicated therapeutic research team |
| gptkbp:research_focus |
personalized medicine
|
| gptkbp:revenue |
€20 million
|
| gptkbp:strategic_goals |
expand product pipeline
|
| gptkbp:subsidiary |
Medigene Immunotherapies Gmb H
|
| gptkbp:technology |
T-cell receptor technology
|
| gptkbp:therapeutic_advancements |
advancements in therapeutics
|
| gptkbp:therapeutic_platforms |
multiple therapeutic platforms
|
| gptkbp:traded_on |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.medigene.com
|
| gptkbp:bfsParent |
gptkb:Medi_Gene_Inc.
|
| gptkbp:bfsLayer |
6
|